Table 5 Oversight committee split by intervention type
Intervention type | TSC reported | DMC reported | |||||||
|---|---|---|---|---|---|---|---|---|---|
Yes | No | Yes | No | ||||||
N | n | n/N% | n | n/N% | n | n/N% | n | n/N% | |
Pharmaceutical | 132 | 68 | 51.5% | 64 | 48.5% | 97 | 73.5% | 35 | 26.5% |
Cellular and gene therapy | 3 | 0 | 0.0% | 3 | 100.0% | 2 | 66.7% | 1 | 33.3% |
Medical device | 26 | 17 | 65.4% | 9 | 34.6% | 19 | 73.1% | 7 | 26.9% |
Surgery | 14 | 9 | 64.3% | 5 | 35.7% | 9 | 64.3% | 5 | 35.7% |
Radiotherapy | 13 | 7 | 53.8% | 6 | 46.2% | 5 | 38.5% | 8 | 61.5% |
Psychological and behavioural | 29 | 14 | 48.3% | 15 | 51.7% | 11 | 37.9% | 18 | 62.1% |
Physical | 14 | 11 | 78.6% | 3 | 21.4% | 8 | 57.1% | 6 | 42.9% |
Complimentary | 6 | 3 | 50.0% | 3 | 50.0% | 2 | 33.3% | 4 | 66.7% |
Resources and infrastructure | 22 | 13 | 59.1% | 9 | 40.9% | 5 | 22.7% | 17 | 77.3% |
Other | 19 | 13 | 68.4% | 6 | 31.6% | 7 | 36.8% | 12 | 63.2% |